KR101521341B1 - Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract - Google Patents

Abstract

The present invention relates to a pharmaceutical composition and a health functional food composition for prevention or treatment of anorexia nervosa containing an extract of northern pork, northern pork roots, northern pork sardine or northern pork malt enzyme as an active ingredient, and an animal feed additive composition for promoting appetite . As a result, the extracts of northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme can be used as a composition for preventing or treating an appetite stimulation or anorexia and dietary disorders, as well as being useful as a health functional food have.
Also, the herbal medicine extract according to the present invention can be easily used as an animal feed additive for appetite promotion.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention or treatment of anorexia nervosa comprising an extract of northern pork, northern pork, northern pork sirloin or northern pork malt enzyme as an active ingredient. TECHNICAL FIELD The present invention relates to a composition for prevention or treatment of anorexia nervosa comprising anorexia, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperm dauricum DC malt fermented liquid extract}

The present invention relates to a pharmaceutical composition, a health functional food composition, and an animal feed additive composition for promoting appetite, which comprises an extract of northern pork, northern pork roots, northern pork pork nor bamboo pork malt enzyme solution as an active ingredient .

Anorexia is defined as a lack of or desire for food. Appetite is mainly regulated in the hypothalamus but is regulated by the hypothalamus, physical stimulation of the digestive tract, body fluid components such as blood sugar and free fatty acids, and hormones. Temporal anorexia resumes spontaneously over time, but long-lasting anorexia is becoming more and more prevalent because of the increased severity of symptoms and other symptoms such as coughing and depression.

Typical examples of such anorexic symptoms include elderly people, chronic disease patients, and patients suffering from acute conditions or diseases.

Lack of appetite in the elderly can be caused by various causes due to clinical symptoms. In the case of the elderly, there may be a loss of appetite due to a physiological change due to aging, and a loss of appetite due to psychological factors. In addition, although it may occur due to various causes such as side effects of the drug due to the disease, about 1/4 of the elderly patients can not find the cause, serious nutritional disorders and weight loss occur, and the morbidity and mortality rate of the disease is increased, In the case of sluggishness, active treatment is required. In the case of foreign countries, studies on the loss of weight of the elderly and anorexia have been conducted, but there have been no systematic researches in Korea yet. In the oriental medicine field, literature review on anorexia and anorexia nervosa There is no clinical report or review of the poor appetite of the elderly.

In addition, symptoms of appetite reduction appear in patients receiving cancer chemotherapy, immunodeficiency caused by AIDS disease, immunosuppressed patients by organ transplantation, and other patients after surgery.

In particular, the causes of anorexia nervosa, which causes a primary disorder during anorexia, include psychological factors such as depression, hormone abnormality such as gastrointestinal digestion and absorption disorder, adrenal insufficiency, pituitary dysfunction, and electrolyte loss. Involvement of the multiple factors causes anorexia and causes therapeutic problems.

In addition, anorexia nervosa, such as anorexia, is a psychotic symptom such as a characteristic aspiration of emaciation and abnormal eating behavior, and exhibits somatic symptoms such as weight loss of more than 20% of the standard weight. It often occurs in young women and can be a serious and sometimes fatal disease.

Therefore, when the appetite is poor or the digestive power is weakened, various formulations for promotion of appetite promotion and promotion of digestion are often used, and a fermentation agent containing a large amount of digestive enzymes is popular. The core material is a preparation such as a "raw flour" in which a yeast containing a large amount of digestive enzymes such as amylase, peptidase, etc. is cultured and dried and tabletted. In addition, vitamins, various digestive enzymes, or most directly stimulating appetite centers are formulated with various vitamins and minerals. As the agent for stimulating the appetite center, products such as "TRANSSTANE" and "EPISCAPSEL" which inhibit serotonin binding to the serotonin receptor of the satiety center are commercially available, and serotonin This is based on the principle that the orotosaccharide heptadine compound binds to the receptor instead of serotonin to make it feel less full-bodied. However, drugs such as these have a direct effect on the administration, but when the digestive or appetite stimulation alone does not activate other organs, the ingestion of the food as soon as the appetite is pulled causes a problem of worsening the disease .

In addition, megestrol acetate, which is currently approved as an appetite stimulant, has anti-estrogenic properties that interfere with estrogen receptor replacement. It inhibits the normal estrogen cycle and lowers the blood LH level and causes petechiae, menstrual disorders, amenorrhea, Indicates side effects. Thus, although megestrol acetate is a specialized medicine approved as an appetite stimulant, the mechanism of appetite stimulation of a drug is not known and is not suitable for use for healing purposes due to a poor appetite simply because it is used as a cancer adjuvant.

Therefore, there is a need to develop a material having an endocrine system side effect and an effective anorexia improvement effect without toxicity.

On the other hand, the Menispermum dauricum DC is also called a new sand vine, belongs to the Menispermaceae, and the rootstock is used for medicinal purposes. The efficacy is effective for tonsillitis, laryngitis, chronic bronchitis, bladder adenomatous polyposis, rhinosomes, hygromycosis and athlete's joint arthritis, and is also effective for dysentery, enteritis, limb paralysis, stomach pain, stomach pain and abdominal distension.

Under the circumstances described above, the inventors of the present invention have been studying natural medicines having an excellent appetite suppression effect or therapeutic effect without adverse side effects and toxicity, and have found that when extracts of northern pork, northern pork, northern pork saury or northern pork malt enzyme solution are administered to anorexic animals The present inventors have completed the present invention by confirming that the present invention has the effect of effectively increasing the food intake.

It is an object of the present invention to provide a pharmaceutical composition or a health functional food composition having an excellent prevention or therapeutic effect on anorexia nervosa containing an extract of North Rhinestone, North Rhinestone Root, North Rhinoceros nucifera or North Rhinosinus malt enzyme as an active ingredient .

Another object of the present invention is to provide an animal feed additive composition for promoting an appetite, which comprises as an active ingredient an extract of northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme solution.

In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating anorexia nervosa comprising, as an active ingredient, an extract of northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme solution.

The term "Northern excited" to be used in the present invention, the nomenclature Menispermum dauricum DC , also called a new sand vine, is a plant belonging to the family Menispermaceae. It is distributed in various parts of Southeast Asia including China, Manchuria, and Siberia including Korea, and it is collected in April-May or August-October, and it is used to dry and remove soil and soil. The composition of the present invention may include extracts of bamboo beetle, bamboo beet root extract, bamboo bamboo sieve or bamboo shoot malt enzyme solution. At this time, the north beef refers to a ground product obtained by crushing the beet root, and may be ground one to three times using a crusher.

The term "extract" as used in the present invention means a specific component separated from the nasal psoriasis using a liquid solvent. The solvent is preferably water, C _{1 -4} alcohol or a mixed solvent thereof. The extraction method can be selected from the group consisting of reflux cooling extraction, hot water extraction, ultrasonic extraction, room temperature extraction, cold extraction and steam extraction. In order to efficiently extract the active ingredient, it is preferable to use a reflux cooling extraction method Do. In addition, the extraction is preferably performed for 1 to 24 hours, more preferably for 1 to 5 hours. In addition, the extraction of the present invention can be carried out once to several times, more preferably three times.

The extract may be obtained in liquid or powder form, if necessary, by concentration under reduced pressure or drying under reduced pressure at a temperature in the range of 20 ° C to 100 ° C, preferably 30 ° C to 70 ° C.

As used in the present invention, the term " bamboo beetle sludge " means a substance such as a mackerel that has not been filtered after extracting bamboo beet root, and can be obtained by a commonly used method. For example, the sludge obtained by extracting northern muscles and filtering may be formed into a powder form by drying at a temperature of 20 ° C to 70 ° C, more preferably 40 ° C to 60 ° C.

As used herein, the term " northern thyme malt enzyme solution extract "means a specific ingredient separated from a liquid of maltose by reacting northern thigh with malt enzyme solution. Preferably, the extract of northern pork malt enzyme solution is prepared by adding the bovine psoriasis to a malt enzyme solution, reacting the solution at a temperature ranging from 30 ° C to 70 ° C for 1 hour to 12 hours and then extracting with water, C _{1 -4} alcohol or a mixed solvent thereof .

It is preferable that the bovine roots and the malt enzyme solution are mixed at a weight ratio of 0.1 to 50:50 to 99.9. If the mixing ratio of the north beet root exceeds 50 weight ratio, mixing may not be easy. The malt enzyme solution is preferably prepared by adding malt to the water in an amount of 0.1% by weight to 99% by weight and mixing for 0.5 to 24 hours and filtering. At this time, the temperature is preferably 20 ° C to 50 ° C, more preferably 20 ° C to 40 ° C. If mixed at a temperature higher than 50 ° C, the enzyme activity of the malt enzyme solution may significantly decrease, and the extraction yield of the malt enzyme solution may be lowered at a temperature lower than 20 ° C.

The term "prevention" as used in the present invention means any action that inhibits or delays anorexia by administering a composition containing the northern bosom, northern bosom extract, northern boson sory or northern bosomal malt enzyme solution extract. As used herein, the term "treatment" as used in the present invention refers to any action that improves or alleviates symptoms of anorexia due to administration of a composition containing the northern bark, the bark extract, the bark extract or the bark extract. do.

The composition of the present invention may contain, for administration, a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described effective ingredients. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The composition of the present invention may be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like oral preparation, external preparation, suppository or sterilized injection solution according to a conventional method. In detail, when formulating, it can be prepared by using diluents or excipients such as fillers, weighing agents, binders, humectants, disintegrants, surfactants and the like which are generally used. Solid formulations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation can be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like in the extracts of northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme solution. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration, liquid paraffin, and various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like. Formulations for non-occasional administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and tasks. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As a base for suppositories, it is possible to use witepsol, macrosole, tween 61, cacao paper, laurin, glycerogelatin and the like.

The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the desired method, and the dose may be determined depending on the condition and weight of the patient, The mode of administration, the route of administration, and the time, but may be suitably selected by those skilled in the art. The daily dose of the northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme solution extract is preferably 1 mg / kg to 1500 mg / kg, and may be administered once to several times per day .

The present invention also provides a health functional food composition for preventing or ameliorating anorexia nervosa comprising, as an active ingredient, an extract of northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme solution.

The health functional food may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It can also contain flesh for the production of natural fruit juices, fruit juices and vegetable drinks. These components may be used independently or in combination. The health functional food may be in the form of any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, .

In addition, the health functional food may further include food additives, and the suitability of the food functional food as a "food additive" is not limited to the corresponding items in general rules and general test methods approved by the Food and Drug Administration Shall be determined according to the relevant standards and standards.

Examples of the products that have been used in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, sensory coloring matter, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent and the like.

At this time, the content of the bean root, the bean curd extract, the bean curd sowle or the bean curd malt enzyme solution according to the present invention, which is added to foods containing beverages in the process of manufacturing the health functional food, Preferably, it is added so as to include 1 wt% to 80 wt% in 100 wt% of the food.

In addition, the present invention provides an animal feed additive composition for promoting an appetite, comprising as an active ingredient an extract of northern bark, northern bark extract, northern bark sardine or northern bark malt enzyme solution.

The herbal medicine extract according to the present invention is a natural extract effective for the improvement of anorexia, and can be used not only as a pharmaceutical composition for the promotion of appetite stimulation or for the prevention or treatment of anorexia and dietary disorders, but also as a health functional food.

Also, the herbal medicine extract according to the present invention can be easily used as an animal feed additive for appetite promotion.

FIG. 1 shows the results of the maximum potency assay of megestrol acetate (control drug) in an animal model of acute anorexia induced by cisplatin according to one embodiment of the present invention.
FIG. 2 shows the results of a comparative analysis of the effect of accelerating appetite stimulation of the extracts of the beetle root in an acute anorectic animal model induced by cisplatin according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, the following Examples and Experimental Examples are provided for illustrating the present invention, and the scope of the present invention is not limited by these Examples and Experimental Examples.

Example  One: North Pole Crushed  Produce

100 g of bamboo beet pulp was firstly pulverized using a pulverizer, and then pulverized twice more to prepare 100 g of pulverized beet pulp, which was stored at room temperature.

Example  2: North Pole  Preparation of extract

100 g of bamboo shoots were pulverized and immersed in 1 L of 95% ethanol, refluxed at 79 ° C for 3 hours and filtered to obtain a filtrate. The obtained filtrate was concentrated under reduced pressure and then lyophilized to obtain about 14 g of bokyang root extract, which was stored frozen until used in the experiment.

Example  3: North Pole  malt Enzyme solution  Preparation of extract

The extracts of the beetle root were prepared by using malt enzyme solution. First, 100 g of malt was added to 1 liter of water, and the malt enzyme was extracted by using a stirrer at room temperature (about 24 ° C) for 1 hour, followed by filtration to obtain a malt enzyme solution.

100 g of pulverized beet pulp was added to 1 liter of the obtained malt enzyme solution, and the beak pulp was reacted with the malt enzyme solution using a stirrer at 50 ° C for 4 hours. Then, 3 L of ethanol was added to the mixture of bovine roots and malt enzyme solution to make 75% ethanol, and the mixture was refluxed for cooling at 79 DEG C, and then filtered to obtain a filtrate. The obtained filtrate was concentrated under reduced pressure, and then lyophilized to obtain about 22 g of bovine thigh malt enzyme solution. The extract was stored frozen until used in the experiment.

Example  4: North Pole Sour  Produce

100 g of bamboo shoots were pulverized and immersed in 1 L of 95% ethanol, refluxed and extracted at 79 DEG C for 3 hours, and filtered to obtain a filtrate. The remaining sludge after filtration was spread evenly over a period of 24 hours at a temperature of 50 ° C and dried to finally produce 66 g of sardine syrup, which was stored at room temperature.

Experimental Example : An improvement of anorexia

In order to confirm the effect of the extracts prepared from Example 2 and Example 3 on the improvement of appetite loss, the degree of appetite promotion was confirmed using a cisplatin-induced acute appetite-decreasing animal model.

1) Analysis of the highest drug concentration of the reference drug

To compare the effects of the extracts of Examples 2 and 3 on the anorexia nervosa, the highest drug efficacy was determined by administering megestrol, a reference drug, to the experimental animals.

In the experimental animal model of acute appetite lowering, male rats of 7 weeks old and male rats of 8 weeks old (250 g to 270 g), which had been subjected to a weekly purifying period, were used. Eight groups (normal, negative, and positive control) were divided into 7 groups for each group, and they were fasted for 24 hours in a state where they could freely consume water. In the third group, megestol acetate was diluted in 0.5% MC (methylcellulose) twice a day (18 hours after fasting and 23.5 hours after the fasting). The rats were given 25 mg / kg (positive control 1) (3 mg / kg) (positive control group 2) or 45 mg / kg (positive control group 3), and the other three groups were administered megestrol acetate 0.5% MC (Methylcellulose) and orally administered to rats at a dose of 50 mg / kg (positive control group 4), 70 mg / kg (positive control group 5) or 90 mg / kg (positive control group 6), respectively. Twenty-four hours after fasting, cisplatin was injected into the abdominal cavity of rats by dissolving 2 mg / kg of rat body weight in 5 ml of water for injection.

Immediately after the administration of cisplatin, rats were placed in a cage and fed with about 50 g of food in a state in which water was freely available, and the intake was recorded. After 24 hours, the amount of food remaining in the rats was measured to calculate the food intake of the rats. The rats were divided into two groups: a group (cisplatin 2 mg / kg alone) (control group) and a control group Were compared with each other. The results are shown in Table 1 and FIG.

division Intake (g / 24hr) Increase in intake (%) Normal group 25.1 ± 3.09 100% Negative control (2 mg / kg cisplatin) 15.3 ± 2.69 0% Positive control 1 (2 mg / kg cisplatin + 25 mg / kg megestrol) 18.2 ± 2.10 * 29.3% Positive control 2 (2 mg / kg cisplatin + 35 mg / kg megestrol) 19.7 ± 2.40 ** 44.4% Positive control group 3 (2 mg / kg cisplatin + 45 mg / kg megestrol) 19.8 ± 2.49 ** 45.7% Positive control group 4 (2 mg / kg cisplatin + 50 mg / kg megestrol) 19.5 ± 2.92 * 43.0% Positive control 5 (2 mg / kg cisplatin + 70 mg / kg megestrol) 20.6 ± 2.91 ** 53.6% Positive control group 6 (2 mg / kg cisplatin + 90 mg / kg megestrol) 18.4 ± 1.46 * 31.8% * And ** mean p <0.05 and P <0.01, respectively, as compared with the negative control group

As shown in Table 1 and FIG. 1, in the cisplatin alone group (negative control group), the food intake was decreased significantly compared with the normal group. In the cisplatin and megestrol acetate-administered groups (positive control groups 1 to 6) It was confirmed that the effect of induction of appetite was reduced and the food intake was increased. According to the above results, the most effective method, 70 mg / kg of megestrol acetate once a day, was orally administered to rats and used in the comparative test.

2) Improvement of appetite lowering effect

The effect of improving the anorexia nervosa of the extracts prepared from Example 2 was confirmed by comparing with megestrol acetate (positive control) of Experimental Example 1 above.

In the animal model of acute appetite deprivation, 8-week-old male rats (250 g to 270 g) were used, which were 7-week-old male rats and subjected to a week-long purifying period. The test group was divided into five groups (normal, negative, positive control, and group 2) of 7 mice each, and fasted for 24 hours in a state in which water was freely available. The extracts of the bean curd lees were diluted in 0.5% MC (methylcellulose) twice (bid: twice a day) after 18 hours of fasting and 23.5 hours after the fasting, and 600 mg / kg The rats were orally administered to the rats at a dose of 70 mg / kg (qd: once a day) in 0.5% MC (methylcellulose) once every 23.5 hours after the fasting according to Experimental Example 1 ). &Lt; / RTI &gt; In all groups, cisplatin was injected into the abdominal cavity of rats after dissolution in cisplatin (2 mg per kg of body weight) in 15 mL of water for 24 hours.

Immediately after the administration of cisplatin, rats were placed in a cage and fed with about 50 g of food in a state in which water was freely available, and the intake was recorded. After 24 hours, the amount of food remaining in the rats was measured to calculate the food intake of the rats, and the difference in food intake was compared between the cisplatin alone group (negative control group) and the bamboo extract group (Example 2 group). The results of the analysis are shown in Table 2 and FIG.

division Intake (g / 24hr) Intake rate (%) Normal group 27.2 ± 3.87 100% Negative control (2 mg / kg cisplatin) 7.82 + - 0.51 ^T 0% Positive control (2 mg / kg cisplatin + 70 mg / kg megestrol) 17.8 ± 4.57 ^* 51.2% Example 1 Group (2 mg / kg cisplatin + bovine root extract 600 mg / kg) 18.1 ± 4.78 ^* 52.8% T was significantly lower than normal group, p <0.05
* &Lt; / RTI &gt; compared to negative control &lt;

As shown in Table 2 and FIG. 2, in the cisplatin alone group (negative control group), the food intake was decreased significantly compared to the normal group. In Example 2, in which cisplatin and northern root extract were administered together, It was confirmed that the loss of appetite was alleviated and the food intake was improved by 51.2%.

3) Improvement of appetite lowering effect of extract of malt extract

The effect of improving the anorexia nerves of the extract of N. malt enzyme solution prepared in Example 3 was compared with that of megestrol acetate (positive control) in Experimental Example 1 above.

In the animal model of acute appetite deprivation, 8-week-old male rats (250 g to 270 g) were used, which were 7-week-old male rats and subjected to a week-long purifying period. The test group was separated into five groups (normal, negative, positive control, and group 3) of 7 mice each, and fasted for 24 hours in a state in which water was freely available. In Example 3, the extract of bovine duodenal malt enzyme solution was diluted in 0.5% MC (methylcellulose) twice (bid: twice a day) after 18 hours of fasting and 23.5 hours after fasting, / kg (rat weight). The positive control group was orally administered at a dose of 70 mg / kg (rat weight) to 0.5% MC once (qd: once a day) only after 23.5 hours of fasting according to Experimental Example 1 described above. After the lapse of time, cisplatin was injected into the abdominal cavity of rats by dissolving 2 mg / kg body weight of rats in 15 ml of injection water.

Immediately after cisplatin administration, one rat was placed in a cage and about 50 g of food was fed in a state in which water was freely available, and the intake was recorded. After 24 hours, the amount of food left in the rats was measured to calculate the food intake of the rats, and the difference in food intake was compared between the cisplatin-only group (negative control group) and the bovine thrips malt enzyme solution extract group (Example 3 group) Respectively. The results are shown in Table 3 below.

division Intake (g / 24hr) Intake rate (%) Normal group 23.2 ± 2.50 100% Negative control (2 mg / kg cisplatin) 10.2 + 4.23 ^T 0% Positive control (2 mg / kg cisplatin + 70 mg / kg megestrol) 14.6 + 4.80 ^* 34.0% Example 2 Group (2 mg / kg cisplatin + bovine thigh malt enzyme solution 300 mg / kg) 15.0 + 5.06 ^* 36.7% T was significantly lower than normal group, p <0.05
* &Lt; / RTI &gt; compared to negative control &lt;

As shown in Table 3, in the cisplatin alone group (negative control group), the food intake was decreased significantly compared to the normal group. In the group 3 of cisplatin and bovine thyroid malt enzyme solution administered together, the cisplatin induced appetite The reduction effect was alleviated and the food intake was increased by 36.7%.

Claims (15)

A pharmaceutical composition for the prevention or treatment of anorexia nervosa comprising, as an active ingredient, an extract of Beetle root, Beetle root extract, Beetle root sieve or Beetle root malt enzyme solution.
The method of claim 1, wherein the beating drum extract pharmaceutical composition to Northern boiled with water, characterized in that the extraction with alcohol or a mixed solvent thereof and the C _{1 -4.}
The method of claim 1, wherein the beating drum Malt enzyme extract is an alcohol or a mixture thereof was added in the book excited on malt enzyme solution and incubated for 1 hour to 12 hours at a temperature ranging from 30 ℃ to 70 ℃ water, C _1-4 Wherein the composition is extracted with a solvent.
[Claim 5] The pharmaceutical composition according to claim 3, wherein the bovine heart muscle and the malt enzyme solution are mixed at a weight ratio of 0.1 to 50:50 to 99.9.
[Claim 5] The pharmaceutical composition according to claim 3, wherein the malt enzyme solution is prepared by adding malt to water and mixing for 0.5 to 24 hours at a temperature ranging from 20 to 60 &lt; 0 &gt; C and filtering.
A health functional food composition for preventing or ameliorating anorexia nervosa containing extracts of beech root, extracts of beetle root, extracts of beetle root, and extracts of beetle root malt enzyme as active ingredients.
7. The method of claim 6 wherein the north boiled extract dietary supplement composition of the book excited with water, characterized in that the extraction with alcohol or a mixed solvent thereof and the C _{1 -4.}
7. The method of claim 6 wherein the north boiled malt enzyme extract is an alcohol or a mixture thereof was added in the book excited on malt enzyme solution and incubated for 1 hour to 12 hours at a temperature ranging from 30 ℃ to 70 ℃ water, C _1-4 Wherein the composition is extracted with a solvent.
The health functional food composition according to claim 8, wherein the bovine heart muscle and the malt enzyme solution are mixed at a weight ratio of 0.1 to 50:50 to 99.9.
The health functional food composition according to claim 8, wherein the malt enzyme solution is prepared by adding malt to water and mixing for 0.5 to 24 hours at a temperature range of 20 to 60 캜 and filtering.
Animal feed additive composition for promoting appetite comprising as an active ingredient an extract of northern pork, northern pork, northern pork sardine or northern pork malt enzyme.
The animal feed additive composition for an appetite stimulating animal according to claim 11, wherein the bamboo shoot extract is extracted with water, C _{1 -4} alcohol or a mixed solvent thereof.
12. The method of claim 11, wherein the beating drum Malt enzyme extract is an alcohol or a mixture thereof was added in the book excited on malt enzyme solution and incubated for 1 hour to 12 hours at a temperature ranging from 30 ℃ to 70 ℃ water, C _1-4 Wherein the animal feed additive composition is an animal feed additive composition for promoting appetite.
14. The animal feed additive composition for an appetite promotion according to claim 13, wherein the bovine muscles and the malt enzyme solution are mixed at a weight ratio of 0.1 to 50:50 to 99.9.
14. The animal feed additive composition for an appetite stimulating agent according to claim 13, wherein the malt enzyme solution is prepared by adding malt to water and mixing the mixture at a temperature of 20 to 60 DEG C for 0.5 to 24 hours and filtering.

Images